06252017Headline:

Dallas-Fort Worth, Texas

HomeTexasDallas-Fort Worth

Email Shezad Malik MD JD Shezad Malik MD JD on LinkedIn Shezad Malik MD JD on Twitter Shezad Malik MD JD on Facebook Shezad Malik MD JD on Avvo
Shezad Malik MD JD
Shezad Malik MD JD
Attorney • (888) 210-9693

FDA Announces Heart Failure Warning for New Diabetic Medications

Comments Off

FDA announces Heart Failure Warning for new diabetic medications, Onglyza and Nesina. Type 2 diabetic patients are at increased risk of heart related complications from their disease and also suffer from life threatening side effects from the newer diabetic medications.

Onglyza Heart Failure Attorney

New type 2 diabetes medications Onglyza and Nesina linked to increased risk of heart failure and death according to FDA.

Over the past several years, medications have been approved for sale that belong to a class known as Incretin Mimetics and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors.

What is Onglyza?

Onglyza (saxagliptin) is made by AstraZeneca. Onglyza was approved by the FDA in 2009, for treatment of type 2 diabetes and is considered a blockbuster drug. Kombiglyze XR is a long-acting version that combines Onglyza and metformin, an older diabetes drug.

FDA Onglyza Heart Failure Warning

The FDA launched a safety review into the Onglyza heart risks in 2014, after a New England Journal of Medicine report, known as “SAVOR.” Researchers discovered an increased rate of heart failure hospitalizations in Onglyza patients compared to those given a placebo or a sugar pill.

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee in 2015, noted that patients were exposed to higher hospitalizations for heart failure and death.

In 2016, the FDA issued a warning, announcing that new heart failure warnings will required for the diabetes drugs Onglyza, Kombiglyze XR, Nesina, Kazano, and Oseni, which are part of a class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors.

The active ingredients in these medications are Saxagliptin and Alogliptin.

Texas Onglyza Heart Failure Lawsuit

Wrendell Chester, from Texas, recently filed a personal injury and product liability lawsuit, against Bristol-Myers Squibb and AstraZeneca, the developers and makers of the drug. Chester claims that the companies failed to adequately warn patients and doctors about the risk of heart failure from side effects of Onglyza and failed to conduct proper research and testing.

According to Chester’s lawsuit in the U.S. District Court for the Southern District of Texas, he suffered serious heart failure injuries after using Onglyza and Kombiglyze XR.

Chester claims that he suffered severe congestive heart failure and respiratory failure, from Onglyza side effects.

If you are a diabetic and think you or a loved one may have developed heart failure after taking Onglyza or Nesina, please call us 888-210-9693.

The Dr Shezad Malik Law Firm is currently investigating and filing Onglyza and Nesina heart failure lawsuits on behalf of injured patients all over the U.S.